| S0356 |
Pulrodemstat (CC-90011) besylate |
Pulrodemstat (CC-90011) besylate (LSD1-IN-7 benzenesulfonate) is a potent and orally active lysine specific demethylase-1 (LSD1) inhibitor that is found to be effective in various tumors. |
Selective |
|
| S8438 |
T-3775440 HCl |
T-3775440 HCl is an irreversible LSD1 inhibitor that is highly selective for LSD1 relative to other monoamine oxidases (e.g., MAO-A and MAO-B), with an IC50 value of 2.1 nmol/L. |
Selective |
LSD1, IC50: 2.1 nM |
| S7680 |
SP2509 |
SP2509 (HCI-2509) is a selective histone demethylase LSD1 inhibitor with IC50 of 13 nM, showing no activity against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. SP2509 induces apoptosis and promotes autophagy. |
Selective |
LSD1, IC50: 13 nM |
| S7574 |
GSK-LSD1 2HCl |
GSK-LSD1 2HCl is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B).
|
Selective |
LSD1, IC50: 16 nM |
| S7795 |
Iadademstat (ORY-1001) 2HCl |
ORY-1001 (RG-6016) 2HCl is an orally active and selective lysine-specific demethylase LSD1/KDM1A inhibitor with IC50 of <20 nM, with high selectivity against related FAD dependent aminoxidases. Phase 1.
|
Selective |
LSD1, IC50: 20 nM |
| S7237 |
OG-L002 |
OG-L002 is a potent and specific LSD1 inhibitor with IC50 of 20 nM in a cell-free assay, exhibiting 36- and 69-fold selectivity over MAO-B and MAO-A, respectively. |
Selective |
LSD1, IC50: 20 nM |
| S7796 |
GSK2879552 2HCl |
GSK2879552 2HCl is a potent, selective, orally bioavailable, irreversible LSD1 inhibitor with Kiapp of 1.7 μM. Phase 1. |
Selective |
LSD1, Ki: 1.7 μM |
